(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||||||||||||||||||||||||||||||||
Ordinary Shares, par value $0.0001 per share* | 06160 | The Stock Exchange of Hong Kong Limited |
Exhibit No. | Description | |||||||
99.1 | Financial Information, furnished herewith | |||||||
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL | |||||||
Exhibit No. | Description | |||||||
99.1 | ||||||||
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |
BEIGENE, LTD. | ||||||||||||||||||||||||||
Date: April 26, 2024 | By: | /s/ Chan Lee | ||||||||||||||||||||||||
Name: | Chan Lee | |||||||||||||||||||||||||
Title: | Senior Vice President, General Counsel |
For the year ended December 31, 2023 | For the year ended December 31, 2022 | |||||||||||||||||||
By Region | Revenue | COGS | Gross Margin ratio | Revenue | COGS | Gross Margin ratio | ||||||||||||||
China | 1,101,951 | 352,706 | 68.0% | 840,032 | 276,729 | 67.1% | ||||||||||||||
Ex-China | 1,356,828 | 27,214 | 98.0% | 575,889 | 9,746 | 98.3% | ||||||||||||||
Total | 2,458,779 | 379,920 | - | 1,415,921 | 286,475 |
Pipeline Products/ Projects | For the year ended December 31, 2023 | For the year ended December 31, 2022 | ||||||
Zanubrutinib | 158,051 | 126,959 | ||||||
Tislelizumab | 83,799 | 88,935 | ||||||
Pamiparib | 8,963 | 11,606 | ||||||
Ociperlimab (BGB-A1217) | 77,717 | 106,608 | ||||||
Bcl-2 (BGB-11417) | 52,548 | 22,377 | ||||||
OX40 (BGB-A445) | 15,757 | 11,215 | ||||||
CDAC (BGB-16673) | 3,584 | 1,071 | ||||||
Other R&D projects | 150,998 | 100,726 | ||||||
R&D collaboration projects | 100,115 | 167,620 | ||||||
Subtotal of external R&D expenses | 651,532 | 637,117 | ||||||
Subtotal of internal R&D expenses | 1,127,062 | 1,003,391 | ||||||
Total | 1,778,594 | 1,640,508 |
Item | Unit | Production or purchase quantity for the year ended December 31, 2023 | Sales quantity for the year ended December 31, 2023 | Stock quantity as of December 31, 2023 | ||||||||||
Key products | vials | 5,004,600 | 3,878,000 | 2,666,400 |
Cover |
Apr. 26, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Apr. 26, 2024 |
Entity Registrant Name | BEIGENE, LTD. |
Entity Incorporation, State or Country Code | E9 |
Entity Address, Address Line One | 94 Solaris Avenue, Camana Bay |
Entity Address, City or Town | Grand Cayman |
Entity Address, Postal Zip Code | KY1-1108 |
Entity Address, Country | KY |
Written Communications | false |
Soliciting Material | false |
City Area Code | (345) |
Local Phone Number | 949-4123 |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share |
Trading Symbol | BGNE |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001651308 |
Amendment Flag | false |
Entity Tax Identification Number | 98-1209416 |
Entity File Number | 001-37686 |
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end
MW.5-;ELIZ"YOVP\N(@S#X7=S9M8%C4]I.I:%UX0RJ61.=CY (M]_2YO*MT>C
M3OT $QD?D^&U6KHZBH 31;QY^M31T.?K@X(XDG*Q1L?65I1L\N.^7'4Z'SYX
MQ35HQPO.;@(&W]V+WRF2I'-V\.X/WGW1]/Y^[_*J<_OUYF);KV3